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ABSTRACT
Introduction: The unpredictability of prostate cancer has become a daily challenge for the
urologist, with different strategies being required to manage these cases. In this study, we report on the
perspectives for curing prostate cancer in males undergoing radical prostatectomy with Gleason score
of 2-6 on prostate biopsy in relation to pre-operative PSA levels.
Materials and Methods: From 1991 – 2000, we selected 440 individuals whose pathological
diagnosis revealed a Gleason score of 2-6 upon prostate biopsy and who subsequently underwent
retro-pubic radical prostatectomy due to localized prostate cancer. The clinical stage identified in the
group under study was T1c: 206 (46.8%); T2a: 122 (27.7%); T2b: 93 (21.1%); T2c: 17 (3.9%); T3a:
2 (0.5%). Following surgery, we constructed a biochemical recurrence-free survival curve according
to pre-operative PSA levels between 0-4; 4.1-10; 10.1-20 and > 20 ng/mL, with a median follow-up of
5 years.
Results: Following radical prostatectomy, the pathological stage was confirmed as pT2a:
137 (31.1%); T2b: 118 (26.8%); T2c: 85 (19.3%); T3a: 67 (15.2%); T3b: 6 (1.4%); T3c: 22 (5%).
The biochemical recurrence-free survival, according to PSA values between 0-4; 4.1-10; 10.1-20 and
> 20 ng/mL, was 86.6%, 62.7%, 39.8% and 24.8% respectively.
Conclusion: Better chances for curing low-grade prostate cancer occur in individuals with
normal PSA for whom a biopsy is not usually recommended.
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INTRODUCTION
Approximately 75% of men over 50 years old
are screened for prostate cancer (PCA) through as-
sessment of the prostate specific antigen (PSA) and
digital rectal examination of the prostate (1). This
means there has been an increase in early detection
of PCA with higher likelihood of prostate-confined
disease (2), and lower chances of disease recurrence
following treatment, thus reducing mortality (3).
However, there are controversies about the cost-ben-
efit relationship in PSA screening as well as on the
best time for indicating prostate biopsies in suspected
cases. This becomes even more relevant at a PSA
range of from 2.5 to 4 ng/mL. While this is usually
considered normal, it can nevertheless predict detect-
able cancer. In order to stimulate this debate, recently
Thompson et al. (4) identified PCA in 23.9 % of males
with PSA between 2 and 3 ng/mL and 26.9% of males
with PSA between 3 and 4 ng/mL.
Due to the heterogeneous features of PCA and
the difficulties for predicting its evolution, this study
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is intended to assess individuals with low-risk PCA
(defined as Gleason score 2-6 upon biopsy) who un-
derwent radical prostatectomy, and their post-opera-
tive clinical outcomes in relation to the initial PSA
levels that led to the diagnosis.
MATERIALS AND METHODS
This retrospective study consisted of 440 men
clinically diagnosed with PCA, presenting a Gleason
score of 2-6 on prostate biopsy, with a mean age of
62.5 ± 7.4 years of age (40-79), a mean pre-operative
PSA of 8.7 ± 5.6 ng/mL (0.3-32.0), and median fol-
low-up of 60 months (2-130). Only 4 patients (0.9%)
were lost during the follow-up period.
Initial PSA was collected before the pros-
tate biopsy. During staging, all patients underwent
anamnesis and physical examinations, a dosing of
alkaline phosphatase, total and prostatic acid phos-
phatase, pelvic computerized tomography and bone
scintigraphy in order to rule out extra-prostatic dis-
ease.
All participants underwent radical retro-pu-
bic prostatectomies with bilateral pelvic iliac lym-
phadenectomies at our institution over the period of
March 1991 to November 2000. The same surgeon
performed all surgical procedures and pathological
analyses were conducted by the same pathologist.
Clinical staging was defined based on the
American Joint Committee on Cancer classification
(5), and histological grades according to Gleason
scores (6).
In selecting the group, we excluded cases that
had received neoadjuvant or adjuvant hormone
therapy (14 patients), and adjuvant radiotherapy (one
patient), as well as cases presenting Gleason scores
higher than 6 on biopsy.
Post-operatively, patients were assessed ev-
ery 2 months during the first year, then every 6 months
for 5 years, and from then on, yearly. During each
assessment, the patient underwent a digital rectal ex-
amination of the prostate cavity and analysis of the
serum PSA. Imaging tests (chest radiography, bone
scintigraphy, abdominal tomography) were repeated
every year. Biochemical progression was defined as
a serum PSA equal to or higher than 0.4 ng/mL, a
cut-off level that has been used by other research au-
thors as well (7).
Pre-operative serum PSA was divided into
categories from 0 to 4 ng/mL, 4.1 to 10 ng/mL, 10.1
to 20 ng/mL and higher than 20 ng/mL. The patient
distribution according to clinical stages is listed in
Table-1, and patients according to pre-operative PSA
are listed in Table-2.
For statistical analysis, we used a survival
analysis approach and considered the biochemical
recurrence of disease an event of interest. This was
defined by PSA values equal to or higher than 0.4 ng/
mL. The Kaplan-Meier method and Log-Rank test
were used for the disease-free survival curves. On
multivariate analyses, we adjusted a Cox regression
model with proportional risks. A significance level
of 5% (p < 0.05) was adopted.
RESULTS
During a median follow-up of 60 months (2-
130.5), 109 (24.8%) of the 440 patients under study
presented biochemical recurrence.
Table 2  –  Patient distribution according to pre-operative
PSA levels.
PSA Levels
0 to 4.0
4.1 to 10.0
10.1 to 20.0
> 20.0
  N (%)
043 (10)
234 (53)
123 (28)
040   (9)
Clinical Stage
T1c
T2a
T2b
T2c
T3a
Total
N (%)
206   (46.8)
122   (27.7)
093   (21.1)
017     (3.9)
002     (0.5)
440 (100.0)
Table 1 – Patient distribution according to clinical stag-
ing  (AJCC, 1992).
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Figure-1 represents a graphic display of the
440 men under study on different PSA scales, and
considering a biochemical recurrence of the disease
as an event of interest. Biochemical recurrence-free
survival rates were 86.6% for PSA values of between
0-4, 62.7% for values of between 4.1-10, 39.8% for
values of between 10.1-20 and 24.8% for values > 20
ng/mL. We observed that PSA significantly influenced
disease-free survival (p < 0.001). Among the four
patients with PSA between 0 and 4.0 who presented
recurrence of the disease, two of them had clinical
stage T2a and another 2 had clinical stage T2b. Pa-
tient distribution according to pathological stage is
represented in Table-3.
Figure-2 represents the overall biochemical
recurrence-free survival in the group under study.
The analysis of relative risk for PSA in the
Cox regression model reveals that there is no statisti-
cal difference when PSA levels lower than 4.0 ng/mL
are compared to PSA levels between 4-10 ng/mL,
despite a percentage difference of 23.9%, with se-
rum PSA being an independent prognostic factor for
disease free survival in the post-operative period
(Table-4).
COMMENTS
Our study showed that the likelihood of
biochemical recurrence-free survival in PCA patients
with low Gleason scores, which are usually consid-
ered favorable when these patients undergo radical
prostatectomy, should be looked at more carefully
even when the PSA level is lower than 4.
Increasing the dosing of PSA for screening
PCA has enabled early diagnosis and management of
this disease, so that significant changes have occurred
in the field over the past 2 decades. Coincidently with
these advancements, technical modifications in radi-
cal prostatectomy techniques have provided lower
morbidity, thus reaching progression-free and cancer-
specific survival rates of 68% and 97% respectively
in 10 years (8).
Men with non-palpable PCA detected with
PSA between 2.6 and 4 ng/mL have lower tumoral
volume and organ-confined disease more frequently
than those with PSA between 4.1-10 ng/mL (2). A
positive predictive value for PCA between 6.6 and
26.9% was associated with PSA values between 4-10
ng/mL. Moreover, men diagnosed with localized PCA
with PSA values between 3.1 and 4 ng/mL already
present a high-grade tumor in 25% of cases (9).
The limitations of PSA use and, more spe-
cifically, false positives and false negatives, are well
known. Several investigators have tried to improve
the method’s sensitivity and specificity, including
using PSA adjusted by age, as well as PSA density,
velocity and fractions.
     N (%)
137   (31.1)
002     (0.5)
118   (26.8)
003     (0.7)
085   (19.3)
067   (15.2)
006     (1.4)
022     (5.0)
440 (100.0)
Table 3 – Patient distribution according to pathological
stages.
Pathological Stage
T2a
T2a, NX
T2b
T2b, NX
T2c
T3a
T3b
T3c
Total
Table 4 – Analysis of relative risk for PSA in Cox Regression Model.
Variable
    PSA
(4.1 a 10 / 0 a 4.0)
(10.1 a 20 / 0 a 4.0)
(> 20 / 0 a 4.0)
        Relative Risk
      2.22
      3.83
      6.17
   95% CI
[0.79 -   6.22]
[1.36 - 10.74]
[2.09 - 18.21]
p Value
  0.128
  0.011
  0.001
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Figure 1  –  Survival probability curve for biochemical recurrence of disease according to PSA categories.
Figure 2  –  Probability curve of overall biochemical recurrence-free survival.
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The incidence of PCA in individuals with
PSA between 2 and 3 ng/mL is 23.9%, and rises to
26.9% when PSA oscillates between 3 and 4 ng/mL
(4). Such data are in opposition with the findings of
other studies that have identified PCA in men with
PSA lower than 4 ng/mL, thus advocating early pros-
tate biopsy.
When stratifying patients that had undergone
radical prostatectomies into PSA categories over 10
years, Roehl et al. (8) identified biochemical recur-
rence-free survival rates of 78% – 91% for PSA < 4
ng/mL and 74% for PSA of 4.1-10 ng/mL, while our
study reveals biochemical recurrence-free survival
rates over 5 years of 86.6% and 62.7% for PSA < 4
and 4.1-10 ng/mL respectively.
The probability of identifying PCA when PSA
is between 2.5-4.0 ng/mL in different studies ranges
from 20 to 26% (10,11), and from 24 to 26.5% with
PSA between 2-4 ng/mL (12,13) on the first biopsy
and 13% on the second biopsy (13). In the individuals
whose PSA levels oscillate between 2.0-4.0ng/mL, the
use of complexed PSA can improve the specificity and
diagnostic sensitivity over the total PSA total (14), as
well as reduce the number of unnecessary biopsies (12).
When performing a study similar to ours, Bhatta-Dhar
et al. (15) selected 336 patients with low-risk tumors
(PSA < 10 ng/mL, Gleason score = 6, clinical stage
T1-2), and after a 6-year follow-up, identified 86% to
88% biochemical recurrence-free survival.
The probability of the PCA being organ-con-
fined in individuals with PSA between 2.6-4.0ng/mL
is 77%, and 67% with a PSA between 4.1-10 ng/mL
(10). Another study identified 92% of confined PCA
when the PSA was between 2-4 ng/mL (12). These
data speak for themselves, and even with PSA lower
than 4.0 ng/mL, extra-prostatic disease is identified
in 23% of cases undergoing curative management.
Additionally, with PSA < 4.0 ng/mL, significant PCA
is identified on the biopsy in 67.6% of cases (12).
We disagree with Bastian et al. (16), who
consider that the majority of non-palpable tumors are
insignificant. Our opinion is that non-palpable tumors
can develop aggressive behavior; our sample reveals
biochemical recurrence following treatment in 13.4%
of individuals with PSA lower than 4.0 ng/mL and
27.3% when PSA ranges from 4.1-10 ng/mL.
A possible limitation of our study, we believe,
is that perhaps these data cannot be applied to a non-
Caucasian population. Additionally, since it is a ret-
rospective analysis, sub-staging of Gleason scores on
biopsy could eventually have occurred. However, the
fact that is a homogeneous group with mean follow-
up of 5 years and minimal losses during follow-up
can be highlighted as positive factors.
Though the indiscriminate use of PSA can
diagnose insignificant tumors with low biological
aggressiveness (17), it can be a transitory reality. As
an example, we point out the study of PCA patients
under careful investigation who, after 3.8 years of
follow-up, showed an elevation in Gleason score in
24% of cases (18). Another study, conducted by
Albertsen et al. (19), which assessed 767 men between
55 and 74 years of age under careful investigation
showed that the risk of death due to progressive dis-
ease after 15 years increases according to the Gleason
score in the following proportions: 2-4 (4-7%), 5 (6-
11%), 6 (18-30%), 7 (42-70%) and 8-10 (60-87%).
This situation is more dramatic since, despite
the risk of over treating PCA, currently 25% of men
undergoing radical prostatectomy will require a sec-
ond treatment in the first 5 years following surgery
(20). Based on these data, we wonder if waiting for
the PSA to exceed 4 ng/mL is a correct approach for
these men. This could be the reason many authors
discuss the indication of prostate biopsy, assuming
PSA values of 2.6 ng/mL as upper normal level (2.10-
13).
CONCLUSIONS
When considering the variability in the natu-
ral course of PCA and the apprehensiveness of the
best moment for indicating prostate biopsy based
on PSA, we propose a change in the paradigm if we
wish to increase the real chances of cure, by indi-
cating prostate biopsy in men with PSA between 2.5-
4.0 ng/mL.
Adriana Sanudo performed the statistical analysis
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